Tina Wang is the Portfolio Manager for the HTA programme at the Centre for Innovation in Regulatory Science (CIRS). She received her undergraduate degree in Applied Chemistry from the Beijing University of Technology and a Master of Science in Pharmaceutical Analysis and Quality Control from Kings College, University of London. Prior to joining CIRS in 2010, Ms Wang worked as a research scientist at Medpharm and GlaxoSmithKline.
At CIRS, Ms Wang’s scope of responsibilities covers HTA programme activities, including the HTA Industry Metrics programme, and Regulatory and Reimbursement Atlas Programme. Most recently, she served as co-author of the publication R&D Briefing 53 Availability of new medicines: Characterising the factors influencing drug roll out to six mature markets. Ms Wang’s main field of interest is the international pharmaceutical strategy and policy in Regulatory Affair and Health Technology Assessment.